Skip to main content

Home/ health information/ Group items tagged long-acting-injectable-cabotegravir

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
pharmacybiz

GSK licenses Aurobindo,Cipla,Viatris for cabotegravir - 0 views

www.pharmacy.biz/ons-of-injectable-cabotegravir

gsk-licensing-agreements pharmacy-business injected-drug-cabotegravir-licensing-agreements long-acting-injectable-cabotegravir cabotegravir-for-hiv-prevention

shared by pharmacybiz on 31 Mar 23 - No Cached
  • pharmacybiz on 31 Mar 23
     
    British drugmaker GSK has signed deals with three companies allowing them to make inexpensive generic versions of its long-acting HIV preventive medicine for use in lower-income countries, where the majority of new HIV cases occur. The injected drug cabotegravir is approved by regulators in Britain and the United States. Last July, GSK announced a program with the United Nations-backed healthcare organisation, the Medicines Patent Pool, aiming to get poor countries access to new HIV therapies far earlier than they did for previous HIV medicines. During the HIV/AIDs epidemic in Africa in the 1990s and early 2000s, in which many millions of people died, treatments used widely in wealthy countries were unavailable on the continent. GSK said last year the new program could result in the generic form of its injection being available in lower-income countries beginning in 2026. The drugmaker's HIV treatment division, ViiV Healthcare, said in a statement on Wednesday it had issued voluntary licenses - waiving intellectual property rights - to Aurobindo, Cipla and Viatris, which will manufacture the generic versions of injectable cabotegravir.
pharmacybiz

NICE recommends first long-acting injectable treatment for HIV-1 infection - 0 views

www.pharmacy.biz/-treatment-for-hiv-1-infection

First-Long-Acting-Injectable-Treatment pharmacy-business pharmacy-news-UK Treatment-For-HIV-1-Infection NICE-UK antiretroviral-tablets cabotegravir

shared by pharmacybiz on 13 Dec 21 - No Cached
  • pharmacybiz on 13 Dec 21
     
    In its first, the National Institute for Health and Care Excellence has recommended the use of long-acting injectable treatment for HIV-1 infection in adults, making around 13,000 people eligible for treatment with cabotegravir with rilpivirine in England. The new treatment aims to keep the number of virus particles in the blood so low that it cannot be detected or transmitted between people. Current treatment for HIV‑1 is lifelong antiretroviral tablets taken each day. Use of cabotegravir with rilpivirine is recommended when there is no evidence tosuspect viral resistance, and no previous failure of other anti-HIV-1 medicines. "Clinical trial results show that cabotegravir with rilpivirine is as effective as oralantiretrovirals at keeping the viral load low," NICE stated. Both are administered as two separate injections every two months, after an initial oral (tablet) lead-in period.
1 - 2 of 2
Showing 20▼ items per page